CBD-heavy cannabinoid medicine for migraine relief
Optimization of Cannabinoids for Development as FDA-Approved Migraine Therapeutics
A fixed 100:1 CBD:THC medicine being developed to help people who have acute migraine attacks.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Schedule 1 Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11195529 on NIH RePORTER |
What this research studies
You would be offered a medicine made mostly of cannabidiol (CBD) with a very small amount of THC (S1-220) aimed at relieving acute migraine attacks. The company is completing the safety, manufacturing, and regulatory work needed to ask the FDA for permission to start a phase 1 human trial after promising preclinical results. The plan emphasizes a fast-acting formulation to stop attacks and to provide a safer, standardized alternative to unmonitored cannabis use. If the FDA clears the IND, the team intends to begin first-in-human testing to learn about safety and dosing.
Who could benefit from this research
Good fit: Adults who experience acute migraine attacks and have not achieved adequate relief from existing therapies would be the most likely candidates for future trials.
Not a fit: People without migraine, pregnant people, individuals with contraindications to cannabinoids, or those in areas where cannabinoid trials are not permitted may not benefit or be eligible.
Why it matters
Potential benefit: If successful, this could become a rapid-acting, regulated option for people whose migraines are not well controlled by current treatments.
How similar studies have performed: Animal and lab studies and some small uncontrolled human reports suggest cannabinoids can help migraine, but well-controlled clinical trials of standardized CBD/THC combinations are limited.
Where this research is happening
Chicago, United States
- Schedule 1 Therapeutics, INC. — Chicago, United States (Active)
Researchers
- Principal investigator: Pappas, George — Schedule 1 Therapeutics, INC.
- Study coordinator: Pappas, George
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.